TUC is currently approved for the treatment of HER2-positive, metastatic BC and was approved by the FDA for the treatment of HER2-positive, metastatic CRC in 2023 (see above), whereas in advanced NSCLC, an unmet need remains for HER2-targeted therapy. The gene discussed is ERBB2; the disease is colorectal carcinoma.